東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Cancer immunotherapies = solid tumor...

Hays, Priya.

FindBook

Google Book

Amazon

博客來

Cancer immunotherapies = solid tumors and hematologic malignancies /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Cancer immunotherapies/ edited by Priya Hays.
其他題名:	solid tumors and hematologic malignancies /
其他作者:	Hays, Priya.
出版者:	Cham :Springer International Publishing : : 2022.,
面頁冊數:	xvi, 315 p. :ill. (some col.), digital ;24 cm.
內容註:	Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia -- Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
Contained By:	Springer Nature eBook
標題:	Cancer - Immunotherapy. -
電子資源:	https://doi.org/10.1007/978-3-030-96376-7
ISBN:	9783030963767

Cancer immunotherapies = solid tumors and hematologic malignancies /
Cancer immunotherapiessolid tumors and hematologic malignancies /[electronic resource] :edited by Priya Hays. - Cham :Springer International Publishing :2022. - xvi, 315 p. :ill. (some col.), digital ;24 cm. - Cancer treatment and research,v. 1832509-8497 ;. - Cancer treatment and research ;v. 183..

Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia -- Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.

This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

ISBN: 9783030963767

Standard No.: 10.1007/978-3-030-96376-7doiSubjects--Topical Terms:

656051
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45 / C35 2022

Dewey Class. No.: 616.99406

Cancer immunotherapies = solid tumors and hematologic malignancies /
LDR:03103nmm a2200337 a 4500 001 2300792
003 DE-He213
005 20220512102423.0
006 m d
007 cr nn 008maaau
008 230324s2022 sz s 0 eng d
020 $a 9783030963767 $q (electronic bk.)
020 $a 9783030963750 $q (paper)
024 7 $a 10.1007/978-3-030-96376-7 $2 doi
035 $a 978-3-030-96376-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45 $b C35 2022
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b C215 2022
245 0 0 $a Cancer immunotherapies $h [electronic resource] : $b solid tumors and hematologic malignancies / $c edited by Priya Hays.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a xvi, 315 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer treatment and research, $x 2509-8497 ; $v v. 183
505 0 $a Development of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia -- Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
520 $a This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
650 0 $a Cancer $x Immunotherapy. $3 656051
650 1 4 $a Oncology. $3 751006
650 2 4 $a Hematology. $3 808260
650 2 4 $a Genetics. $3 530508
650 2 4 $a Genomics. $3 600531
700 1 $a Hays, Priya. $3 3518588
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
830 0 $a Cancer treatment and research ; $v v. 183. $3 3599629
856 4 0 $u https://doi.org/10.1007/978-3-030-96376-7
950 $a Medicine (SpringerNature-11650)